$EVGN News

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

Evogene (EVGN) Q2 2026 Earnings Call Transcript

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

Evogene Ltd. Q2 2026 Earnings Call Summary

Evogene Ltd (EVGN) (Q2 2026) Earnings Call Highlights: Strategic Pivot to AI-Driven Drug ...

Evogene Ltd. (EVGN) Q2 2026 Earnings Call Transcript

Evogene Reports Second Quarter and First Half 2026 Financial Results

CORRECTION: Evogene Q2 EPS $(0.13) Beats $(0.27) Estimate, Sales $347.000K Beat $325.000K Estimate

Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

Evogene Schedules Second Quarter 2026 Financial Results Release

Evogene and ELEO to develop new oral PCSK9 inhibitors

Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases

Evogene's AgPlenus Subsidiary Introduces Antifungal Potency Predictor

Evogene and Tel Aviv University launch drug discovery initiative

Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery

Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization

Full Transcript: Evogene Q1 2026 Earnings Call

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Evogene Completes First-In-Human Phase 1 Clinical Study Of BMC128, Rationally-Designed Live Bacterial Product Developed By Its Subsidiary, Biomica, In Combination With Nivolumab In Patients With Advanced Solid Tumors